Results 141 to 150 of about 15,373 (177)

Abemaciclib plus fulvestrant in treating hormone-receptor positive, HER2-negative advanced breast cancer-comparing real-world outcomes in England to the MONARCH-2 trial. [PDF]

Br J Cancer
Anderson J, Lawton S, Thackray K, Kipps E.   +3 more
europepmc   +1 more source

Risk of venous thromboembolism with CDK4/6 inhibitor use in breast cancer: a systematic review and meta-analysis. [PDF]

Oncologist
Cortez E, Torres Luna E, Blancerte Ibarra M, Riojas Suárez IE, Garcia-Perdomo HA, Rojas Hernandez CM.   +5 more
europepmc   +1 more source

A pilot translational study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma. [PDF]

Nat Commun
Cobb LP, Dai Y, Molina Ayala M, Ozirmak Lermi N, Hernandez SD, Davis J, Lee S, Lawson BC, Hajek RA, Celestino J, Liu J, Wang L, Soto LMS, Haymaker C, Chen K, Jiang M, Lu W, Sanchez-Espiridion B, Dang M, Hull S, Vining D, Fellman B, Yuan Y, Sood AK, Westin SN, Taylor J, Bevers M, Shafer A, Fleming ND, Lu KH, Gershenson DM, Jazaeri AA.   +31 more
europepmc   +1 more source

Cyclin-dependent kinase 4/6 inhibitors in granulosa cell tumors and their combination with hormonal therapy: a scoping review. [PDF]

Front Oncol
Pacholczak-Madej R, Łupkowski R, Górniak K, Puskulluoglu M.   +3 more
europepmc   +1 more source

The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. [PDF]

Mol Cancer Ther
Ma J, Hegde S, Sergeeva M, Chakraborty B, Wardell SE, McDonnell DP, Huang PQ, Bunker KD, Doñate F, Lackner MR, Samatar AA.   +10 more
europepmc   +1 more source

Comparative effectiveness of CDK4/6 inhibitor plus endocrine therapy combinations in HR-positive, HER2-negative metastatic breast cancer: the inspiration 01 study. [PDF]

Front Pharmacol
Jia Y, Zhang J, Wang X, Hao C, Wang C, Li S, Lu N, Dong G, Zhao W, Jia Y, Huang L, Gu J, Shi Y, Tong Z.   +13 more
europepmc   +1 more source

Dynamic circulating tumor DNA profiling of ESR1 mutations in HR+/HER2- advanced breast cancer: from prognostic biomarker to clinical decision-making - a comprehensive review. [PDF]

Front Oncol
Ren S, Li P, Zhu D, Zhao L, Zhang X.
europepmc   +1 more source

Subsequent Treatments After Progression on Cyclin-Dependent Kinase 4/6 Inhibitors: A Review of the Evidence and a Real-World Data Perspective From Portuguese Hospitals. [PDF]

Cureus
Freitas R, Barroso T, Braga S, Santos CC, Batista M, Chaves A, Cabral S, Fortuna A, Patel V, Araújo J, Duarte T, Cabral TP, Silva S, Viana C, Baptista C, Gonçalves J, Dunões IQ, Eiriz I.   +17 more
europepmc   +1 more source

Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials. [PDF]

ESMO Open
Jhaveri K, Bidard FC, Kalinsky K, Neven P, Rugo HS, Tolaney SM, Litchfield LM, von Laue CC, Traore S, Sapunar F, Li Y, O'Shaughnessy J.   +11 more
europepmc   +1 more source